Global Pharmaceutical Company

The Situation

The initiative had to balance innovative, AI-driven patient support with stringent regulatory requirements. Clinical, Regulatory, Technology, and Patient Advocacy teams each held legitimate veto power. An assistant that felt magical in a demo could not ship if it could not escalate appropriately, explain its reasoning, and operate within defined boundaries.

How I Worked

• Defined a patient experience vision before the model conversation took over the room.
• Established governance frameworks for AI interactions, including clear escalation pathways to clinical support.
• Aligned stakeholders who did not naturally share a common vocabulary—clinicians, regulators, technologists, and advocates.
• Designed the conversational experience and MVP so that “intelligent” never meant “unchecked.”

What Followed

The program concluded with a patient experience vision, a governance framework for AI interactions, including clinical escalation pathways, and an MVP conversational design capable of withstanding regulatory review. The result was a viable foundation for deployment, not merely a demo that could not ship.